Tau protein aggregation is a shared feature in over 20 neurodegenerative diseases (collectively referred to as "tauopathies") ...

Tau protein aggregation is a shared feature in over 20 neurodegenerative diseases (collectively referred to as "tauopathies"). New research led by Boston Children's Hospital challenges the current ...

Researchers identified UBL3 as a regulator that loads PD-L1 into tumor extracellular vesicles, weakening immunotherapy. They ...

Tau protein aggregation is a shared feature in over 20 neurodegenerative diseases (collectively referred to as "tauopathies"). New research led by ...

Kazia Therapeutics , an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, ...

Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease.

Cancer immunotherapy has reshaped cancer treatment by training the body's immune system to recognize and attack tumors. Drugs ...

Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a post-translational modification that modulates ...

Cancer immunotherapy has been a game-changer, but many tumors still find ways to slip past the immune system. New research ...

Ubiquitination is a crucial post-translational modification process where the small protein ubiquitin is attached to target proteins, marking them for degradation or altering their function. This ...

Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia ...